Exploration of Catalytic Properties of CYP2D6 and CYP3A4 Through Metabolic Studies of Levorphanol and Levallorphan

被引:6
|
作者
Bonn, Britta [1 ,2 ]
Masimirembwa, Collen M. [1 ,3 ]
Castagnoli, Neal, Jr. [4 ,5 ]
机构
[1] AstraZeneca R&D, Discovery DMPK, SE-43181 Molndal, Sweden
[2] Univ Gothenburg, Dept Chem, Gothenburg, Sweden
[3] African Inst Biomed Sci & Technol, Harare, Zimbabwe
[4] Virginia Tech, Dept Chem, Blacksburg, VA USA
[5] Edward Via Coll Osteopath Med, Blacksburg, VA USA
关键词
HUMAN CYTOCHROME-P450 2D6; HUMAN LIVER-MICROSOMES; SUBSTRATE-SPECIFICITY; CRYSTAL-STRUCTURES; IN-VITRO; 3A4; ENZYMES; INVOLVEMENT; INHIBITORS; RESOLUTION;
D O I
10.1124/dmd.109.028670
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
CYP2D6 and CYP3A4, two members of the cytochrome P450 superfamily of monooxygenases, mediate the biotransformation of a variety of xenobiotics. The two enzymes differ in substrate specificity and size and characteristics of the active site cavity. The aim of this study was to determine whether the catalytic properties of these isoforms, reflected by the differences observed from crystal structures and homology models, could be confirmed with experimental data. Detailed metabolite identification, reversible inhibition, and time-dependent inhibition were examined for levorphanol and levallorphan with CYP2D6 and CYP3A4. The studies were designed to provide a comparison of the orientations of substrates, the catalytic sites of the two enzymes, and the subsequent outcomes on metabolism and inhibition. The metabolite identification revealed that CYP3A4 catalyzed the formation of a variety of metabolites as a result of presenting different parts of the substrates to the heme. CYP2D6 was a poorer catalyst that led to a more limited number of metabolites that were interpreted in terms to two orientations of the substrates. The inhibition studies showed evidence for strong reversible inhibition of CYP2D6 but not for CYP3A4. Levallorphan acted as a time-dependent inhibitor on CYP3A4, indicating a productive binding mode with this enzyme not observed with CYP2D6 that presumably resulted from close interactions of the N-allyl moiety oriented toward the heme. All the results are in agreement with the large and flexible active site of CYP3A4 and the more restricted active site of CYP2D6.
引用
收藏
页码:187 / 199
页数:13
相关论文
共 50 条
  • [1] Modulation of CYP2D6 and CYP3A4 metabolic activities by Ferula asafetida resin
    Al-Jenoobi, Fahad I.
    Al-Thukair, Areej A.
    Alam, Mohd Aftab
    Abbas, Fawkeya A.
    Al-Mohizea, Abdullah M.
    Alkharfy, Khalid M.
    Al-Suwayeh, Saleh A.
    SAUDI PHARMACEUTICAL JOURNAL, 2014, 22 (06) : 564 - 569
  • [2] Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol
    Fang, J
    Baker, GB
    Silverstone, PH
    Coutts, RT
    CELLULAR AND MOLECULAR NEUROBIOLOGY, 1997, 17 (02) : 227 - 233
  • [3] Involvement of CYP3A4 and CYP2D6 in the Metabolism of Haloperidol
    Jian Fang
    Glen B. Baker
    Peter H. Silverstone
    Ronald T. Coutts
    Cellular and Molecular Neurobiology, 1997, 17 : 227 - 233
  • [4] Hydroxychloroquine is metabolized by CYP2D6, CYP3A4 and CYP2C8, and inhibits CYP2D6, while its metabolites also inhibit CYP3A4 in vitro
    Paludetto, M.
    Kurkela, M.
    Kahma, H.
    Backman, J.
    Niemi, M.
    Filppula, A.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (SUPPL 1) : S78 - S78
  • [5] Comparison of Paeoniflorin and Albiflorin on Human CYP3A4 and CYP2D6
    Gao, Li-Na
    Zhang, Ye
    Cui, Yuan-Lu
    Akinyi, Olunga Mary
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2015, 2015
  • [6] Influence of CYP3A4 and CYP2D6 inhibition on fesoterodine treatment
    Sachse, R
    Cawello, W
    Horstmann, R
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (10): : 1186 - 1186
  • [7] Development of CYP2D6 and CYP3A4 in the first year of life
    Johnson, T. N.
    Tucker, G. T.
    Rostami-Hodjegan, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (05) : 670 - 671
  • [8] Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone
    Kummer, Oliver
    Hammann, Felix
    Moser, Claudine
    Schaller, Olivier
    Drewe, Juergen
    Kraehenbuehl, Stephan
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 67 (01) : 63 - 71
  • [9] CYP3A4 and CYP2D6 inhibitory activities of Indonesian medicinal plants
    Usia, T
    Iwata, H
    Hiratsuka, A
    Watabe, T
    Kadota, S
    Tezuka, Y
    PHYTOMEDICINE, 2006, 13 (1-2) : 67 - 73
  • [10] Generation and validation of rapid computational filters for CYP2D6 and CYP3A4
    Ekins, S
    Berbaum, J
    Harrison, RK
    DRUG METABOLISM AND DISPOSITION, 2003, 31 (09) : 1077 - 1080